Liberate Bio

Liberate Bio develops non-viral delivery technologies for nucleic acid cargoes, aiming to address genetic disorders.

Latest funding

$31M Seed · October 15, 2025

Website: liberatebio.com.

LinkedIn: linkedin.com.

Categories: Health and bio Logistics and mobility.

Sectors: Bioinformatics, Biotechnology, Genetics.

Stage: Seed.

Based in: Boston, United States.

Last round: Oct 15, 2025 · 393 days ago.

On Recent Funding since: Nov 8, 2026.

Signals

Website registeredApr 21, 2022 (4 years old)

MM
Michael Mitchell CO-FOUNDER, UNIVERSITY OF PENNSYLVANIA

source: liberatebio.com
NB
Nessan Bermingham CO-FOUNDER, KHOSLA VENTURES

source: liberatebio.com
SS
Stephen Scully Founder
TM
Theresa M. Reineke CO-FOUNDER, UNIVERSITY OF MINNESOTA

source: liberatebio.com
SD
Shawn Davis Chief Executive Officer
SB
Steven Bernstein Chief Medical Officer

Sources and API

Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/liberate-bio (get a free API key).